{"object":"list","data":[{"slug":"5-amino-1mq","name":"5-Amino-1MQ","class":"non-peptide","regulatory_status":"no-approved-use","status_by_route":[],"pcac_outcome":null,"evidence_grade":"animal-only","access_route_types":["none"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:39:13.835Z","primary_source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026","stale":false},{"slug":"apomorphine","name":"Apomorphine","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:43:54.377Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021264","stale":false},{"slug":"bpc-157","name":"BPC-157","class":"healing-and-repair","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"animal-only","access_route_types":["clinical-trial"],"regulatory_as_of":"2026-10-23","verified":"2026-10-25T06:28:30.677Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"bremelanotide","name":"Bremelanotide","class":"melanocortin","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"moderate-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-24","verified":"2026-10-25T17:34:43.212Z","primary_source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/210557Orig1s005ltr.pdf","stale":false},{"slug":"cagrisema","name":"CagriSema","class":"amylin-analog","regulatory_status":"investigational","status_by_route":[],"pcac_outcome":null,"evidence_grade":"moderate-human","access_route_types":["clinical-trial"],"regulatory_as_of":"2026-10-24","verified":"2026-10-25T06:27:05.656Z","primary_source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","stale":false},{"slug":"cerebrolysin","name":"Cerebrolysin","class":"neuro-and-cognitive","regulatory_status":"no-approved-use","status_by_route":[],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["none"],"regulatory_as_of":"2026-10-25","verified":"2026-10-26T13:32:24.101Z","primary_source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020","stale":false},{"slug":"dihexa","name":"Dihexa","class":"neuro-and-cognitive","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"animal-only","access_route_types":["none"],"regulatory_as_of":"2026-10-25","verified":"2026-10-26T04:05:32.556Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"dsip","name":"DSIP","class":"neuro-and-cognitive","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"insufficient","access_route_types":["none"],"regulatory_as_of":"2026-10-23","verified":"2026-10-26T03:03:12.217Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"epitalon","name":"Epitalon","class":"other","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"animal-only","access_route_types":["none"],"regulatory_as_of":"2026-10-23","verified":"2026-10-25T23:52:32.717Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"finasteride","name":"Finasteride","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:43:55.231Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020180","stale":false},{"slug":"ghk-cu","name":"GHK-Cu","class":"healing-and-repair","regulatory_status":"category-1","status_by_route":["Routes other than injection, such as on the skin: category-1","Injection: limbo"],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["lawful-compounding"],"regulatory_as_of":"2026-10-25","verified":"2026-10-26T03:03:14.806Z","primary_source_url":"https://www.fda.gov/media/94155/download","stale":false},{"slug":"ghrp-2","name":"GHRP-2","class":"growth-hormone-axis","regulatory_status":"no-approved-use","status_by_route":["Shots and nasal sprays: category-2","Other forms, such as by mouth: no-approved-use"],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["lawful-compounding"],"regulatory_as_of":"2026-10-25","verified":"2026-10-26T13:32:22.378Z","primary_source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","stale":false},{"slug":"ghrp-6","name":"GHRP-6","class":"growth-hormone-axis","regulatory_status":"category-2","status_by_route":[],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["none"],"regulatory_as_of":"2026-10-25","verified":"2026-10-26T13:32:23.237Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"glutathione","name":"Glutathione","class":"other","regulatory_status":"category-1","status_by_route":["Compounded by a pharmacy, such as shots, drips and nasal sprays: category-1","Sold as an ingredient in dietary supplements: dietary-supplement"],"pcac_outcome":"The committee recommended adding glutathione to the 503A bulks list, against FDA's proposal to leave it off","evidence_grade":"limited-human","access_route_types":["dietary-supplement","lawful-compounding","clinical-trial"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T20:24:56.431Z","primary_source_url":"https://www.fda.gov/media/94155/download","stale":false},{"slug":"kpv","name":"KPV","class":"healing-and-repair","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"animal-only","access_route_types":["none"],"regulatory_as_of":"2026-10-23","verified":"2026-10-26T03:03:18.376Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"liraglutide","name":"Liraglutide","class":"glp-1-agonist","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-24","verified":"2026-10-25T06:23:45.924Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321","stale":false},{"slug":"ll-37","name":"LL-37","class":"antimicrobial","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["none"],"regulatory_as_of":"2026-10-23","verified":"2026-10-26T03:03:21.588Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"melanotan-ii","name":"Melanotan II","class":"melanocortin","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["none"],"regulatory_as_of":"2026-10-25","verified":"2026-10-26T03:03:26.675Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"melatonin","name":"Melatonin","class":"non-peptide","regulatory_status":"category-1","status_by_route":["Compounded by a pharmacy on a prescription: category-1","Sold as a dietary supplement that is swallowed: dietary-supplement"],"pcac_outcome":null,"evidence_grade":"moderate-human","access_route_types":["dietary-supplement","lawful-compounding","clinical-trial"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:39:16.306Z","primary_source_url":"https://www.fda.gov/media/94155/download","stale":false},{"slug":"methylene-blue","name":"Methylene blue","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T17:05:08.853Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204630","stale":false},{"slug":"minoxidil","name":"Minoxidil","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:43:56.075Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019501","stale":false},{"slug":"mk-677","name":"MK-677","class":"non-peptide","regulatory_status":"category-2","status_by_route":[],"pcac_outcome":"The committee recommended against adding ibutamoren mesylate to the 503A bulks list, as FDA had proposed","evidence_grade":"moderate-human","access_route_types":["clinical-trial"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T20:24:55.616Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"mots-c","name":"MOTS-c","class":"mitochondrial","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"animal-only","access_route_types":["none"],"regulatory_as_of":"2026-10-23","verified":"2026-10-25T23:51:31.514Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"nad-plus","name":"NAD+","class":"non-peptide","regulatory_status":"category-1","status_by_route":[],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["lawful-compounding","clinical-trial"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:39:15.470Z","primary_source_url":"https://www.fda.gov/media/94155/download","stale":false},{"slug":"ondansetron","name":"Ondansetron","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:43:51.014Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020103","stale":false},{"slug":"orforglipron","name":"Orforglipron","class":"glp-1-agonist","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product"],"regulatory_as_of":"2026-10-24","verified":"2026-10-25T17:34:42.327Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934","stale":false},{"slug":"oxytocin","name":"Oxytocin","class":"other","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"moderate-human","access_route_types":["approved-product","lawful-compounding","clinical-trial"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:36:27.817Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018261","stale":false},{"slug":"peg-mgf","name":"PEG-MGF","class":"growth-hormone-axis","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"insufficient","access_route_types":["none"],"regulatory_as_of":"2026-10-25","verified":"2026-10-26T03:03:29.557Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"retatrutide","name":"Retatrutide","class":"dual-or-triple-agonist","regulatory_status":"investigational","status_by_route":[],"pcac_outcome":null,"evidence_grade":"moderate-human","access_route_types":["clinical-trial"],"regulatory_as_of":"2026-10-23","verified":"2026-10-26T00:00:27.207Z","primary_source_url":"https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss","stale":false},{"slug":"semaglutide","name":"Semaglutide","class":"glp-1-agonist","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-23","verified":"2026-10-25T17:34:40.564Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256","stale":false},{"slug":"semax","name":"Semax","class":"neuro-and-cognitive","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["none"],"regulatory_as_of":"2026-10-23","verified":"2026-10-26T03:03:32.493Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"sildenafil","name":"Sildenafil","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:43:51.859Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020895","stale":false},{"slug":"tadalafil","name":"Tadalafil","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:43:52.703Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021368","stale":false},{"slug":"tb-500","name":"TB-500","class":"healing-and-repair","regulatory_status":"limbo","status_by_route":[],"pcac_outcome":null,"evidence_grade":"animal-only","access_route_types":["none"],"regulatory_as_of":"2026-10-23","verified":"2026-10-25T23:50:30.004Z","primary_source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","stale":false},{"slug":"tesamorelin","name":"Tesamorelin","class":"growth-hormone-axis","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"moderate-human","access_route_types":["approved-product"],"regulatory_as_of":"2026-10-24","verified":"2026-10-25T17:34:41.505Z","primary_source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022505Orig1s020ltr.pdf","stale":false},{"slug":"tesofensine","name":"Tesofensine","class":"non-peptide","regulatory_status":"no-approved-use","status_by_route":[],"pcac_outcome":null,"evidence_grade":"moderate-human","access_route_types":["none"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:39:13.025Z","primary_source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025","stale":false},{"slug":"thymalin","name":"Thymalin","class":"other","regulatory_status":"no-approved-use","status_by_route":[],"pcac_outcome":null,"evidence_grade":"limited-human","access_route_types":["none"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:36:26.985Z","primary_source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024","stale":false},{"slug":"tirzepatide","name":"Tirzepatide","class":"dual-or-triple-agonist","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-24","verified":"2026-10-25T06:21:23.561Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806","stale":false},{"slug":"tretinoin","name":"Tretinoin","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:43:56.926Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020475","stale":false},{"slug":"vardenafil","name":"Vardenafil","class":"non-peptide","regulatory_status":"fda-approved","status_by_route":[],"pcac_outcome":null,"evidence_grade":"strong-human","access_route_types":["approved-product","lawful-compounding"],"regulatory_as_of":"2026-10-26","verified":"2026-10-26T13:43:53.543Z","primary_source_url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021400","stale":false}],"total_count":40}